STRENSIQ (asfotase alfa) is a long-term medication specifically designed to treat hypophosphatasia, a rare inherited bone disorder that typically begins in childhood. This specialized treatment helps to address the underlying issues of the disease.
Understanding STRENSIQ
STRENSIQ is a medicine that serves as a long-term treatment for patients diagnosed with childhood-onset hypophosphatasia. Its primary purpose is to provide ongoing therapeutic support, aiming to improve the health outcomes for individuals living with this genetic condition.
What is Hypophosphatasia (HPP)?
Hypophosphatasia is a rare inherited disease that primarily affects the bones. It is a genetic disorder, meaning it is passed down through families, and when it manifests in childhood, its effects can be significant and debilitating.
- Key Characteristics of Childhood Hypophosphatasia:
- Early loss of teeth: This can be one of the earliest signs of the condition.
- Malformed bones: Bones may not develop or mineralize properly, leading to deformities.
- Frequent bone fractures: The compromised bone quality makes patients highly susceptible to breaks.
- Difficulty breathing: In more severe cases, skeletal abnormalities can impact the rib cage and respiratory function.
The Role of STRENSIQ in Treatment
As a long-term therapeutic approach, STRENSIQ aims to mitigate the severe symptoms and progression of childhood-onset hypophosphatasia. By addressing the specific genetic defect that causes poor bone mineralization, STRENSIQ helps to enhance bone strength and reduce the debilitating effects such as skeletal deformities and recurrent fractures, ultimately improving the quality of life for affected individuals.
